Adicet Bio Achieves Fast Track Status for Innovative ADI-001
Adicet Bio's Recent FDA Fast Track Designation Adicet Bio, Inc. (Nasdaq: ACET), a pioneering company at the forefront of biotechnology, is thrilled to announce that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy ADI-001. This designation is a significant step forward for the company, especially in...
Continue Reading